<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30162">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01987817</url>
  </required_header>
  <id_info>
    <org_study_id>ARC001</org_study_id>
    <nct_id>NCT01987817</nct_id>
  </id_info>
  <brief_title>Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen (CPNA)Oral Immunotherapy (OIT)</brief_title>
  <acronym>ARC001</acronym>
  <official_title>Phase 2 Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen (CPNA)Oral Immunotherapy (OIT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergen Research Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergen Research Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind placebo controlled study of efficacy and
      safety of characterized peanut oral immunotherapy in peanut allergic individuals.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The proportion of subjects who tolerate at least 300 mg (443 mg cumulative) of peanut protein with no more than mild symptoms at the exit Double Blind Placebo Controlled Food Challenge (DBPCFC)</measure>
    <time_frame>6-9 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Peanut-Allergic Children and Adults</condition>
  <arm_group>
    <arm_group_label>Peanut Flour</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: Peanut Oral Immunotherapy - Peanut Flour This will be used for dose escalation, build-up, and maintenance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Biological: Placebo for Peanut Oral Immunotherapy - Peanut Flour Similar in appearance and texture to peanut flour</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Characterized Peanut Allergen</intervention_name>
    <arm_group_label>Peanut Flour</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 4 through 26 years

          -  Clinical history of allergy to peanuts or peanut containing foods

          -  Serum IgE to peanut &gt;0.35 kU/L (determined by UniCAP within the past 12 months)
             and/or a SPT to peanut &gt;3 mm compared to control

          -  Experience dose-limiting symptoms at or before the 100mg dose of peanut protein
             (measured as 200 mg of peanut flour) on abbreviated screening OFC conducted via
             PRACTALL guidelines

          -  Use of birth control by females of child bearing potential

        Exclusion Criteria:

          -  History of Cardiovascular disease

          -  History of frequent or repeated, severe or life-threatening episodes of anaphylactic
             shock

          -  History of other chronic disease

          -  History of eosinophilic gastrointestinal disease

          -  Severe asthma

          -  Mild or moderate asthma if uncontrolled

          -  Use of omalizumab within the past 6 months or current use of other non-traditional
             forms of allergen immunotherapy

          -  Use of beta-blockers(oral), angiotensin-converting enzyme (ACE)

          -  Pregnancy, lactation

          -  Having the same place of residence as another study subject

          -  Participation in an interventional clinical trial 30 days prior to randomization
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Hansberry</last_name>
      <phone>501-364-4370</phone>
    </contact>
    <investigator>
      <last_name>Stacie Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Leonard, MD</last_name>
      <phone>858-966-5961</phone>
    </contact>
    <investigator>
      <last_name>Stephanie Leonard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan Laubach, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Little</last_name>
      <email>sara.little@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Rima Rachid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Noone, RN</last_name>
      <phone>212-241-0336</phone>
    </contact>
    <investigator>
      <last_name>Julie Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edwin Kim, MD</last_name>
      <phone>919-962-4824</phone>
    </contact>
    <investigator>
      <last_name>Wesley Burks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edwin Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Vickery, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Clark</last_name>
      <phone>513-636-2733</phone>
    </contact>
    <investigator>
      <last_name>Amal Ass'ad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Pinzone</last_name>
      <phone>267-426-2263</phone>
    </contact>
    <investigator>
      <last_name>Jonathan Spergel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Bird, MD</last_name>
      <phone>214-456-8317</phone>
    </contact>
    <investigator>
      <last_name>John Bird, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>November 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Characterized Peanut Allergen</keyword>
  <keyword>Peanut</keyword>
  <keyword>OIT</keyword>
  <keyword>Oral Desensitization</keyword>
  <keyword>Peanut Allergen</keyword>
  <keyword>Allergy</keyword>
  <keyword>Peanut Allergy</keyword>
  <keyword>Peanut-Allergic Children</keyword>
  <keyword>Children</keyword>
  <keyword>Peanut-Allergic Adults</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
